VRTX

SEC source: 0000875320-24-000034 · wk-form4_1707428861.xml · nonDerivative · entry 1

WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,507

F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest on 02/20/2024.

SEC source: 0000875320-24-000006 · wk-form4_1705525544.xml · derivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,822.483

Underlying: Common Stock · 76.503 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

SEC source: 0000875320-24-000008 · wk-form4_1705525692.xml · derivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,744.258

Underlying: Common Stock · 101.042 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

SEC source: 0000875320-24-000004 · wk-form4_1704920790.xml · nonDerivative · entry 1

LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 2,423

F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 08/04/2023.

F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F3 · price: Open market sales reported on this line occurred at a weighted average price of $419.07 (range $419.00 to $419.21).

SEC source: 0000875320-24-000002 · wk-form4_1704403018.xml · nonDerivative · entry 1

WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 43,693

F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1, which was entered into on 08/18/2023.

SEC source: 0000875320-23-000062 · wk-form4_1703020525.xml · derivative · entry 5

Kewalramani Reshma · CIK 0001735944 · Director · CEO & President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,565

Underlying: Common Stock · 14,077 shares

Expires 2029-02-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Fully vested.

SEC source: 0000875320-23-000062 · wk-form4_1703020525.xml · derivative · entry 4

Kewalramani Reshma · CIK 0001735944 · Director · CEO & President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 3,058 shares

Expires 2028-02-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Fully vested.

SEC source: 0000875320-23-000062 · wk-form4_1703020525.xml · nonDerivative · entry 3

Kewalramani Reshma · CIK 0001735944 · Director · CEO & President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 108,711

F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 08/11/2023.

SEC source: 0000875320-23-000062 · wk-form4_1703020525.xml · nonDerivative · entry 2

Kewalramani Reshma · CIK 0001735944 · Director · CEO & President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 125,846

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000875320-23-000062 · wk-form4_1703020525.xml · nonDerivative · entry 1

Kewalramani Reshma · CIK 0001735944 · Director · CEO & President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 111,769

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000875320-23-000056 · wk-form4_1702675215.xml · derivative · entry 4

Arbuckle Stuart A · CIK 0001557290 · EVP, COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,603 shares

Expires 2029-02-05

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Fully vested.

SEC source: 0000875320-23-000056 · wk-form4_1702675215.xml · nonDerivative · entry 2

Arbuckle Stuart A · CIK 0001557290 · EVP, COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 56,556

F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1, which was entered into on 02/28/2023.

SEC source: 0000875320-23-000056 · wk-form4_1702675215.xml · nonDerivative · entry 1

Arbuckle Stuart A · CIK 0001557290 · EVP, COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 65,159

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000875320-23-000058 · wk-form4_1702675367.xml · nonDerivative · entry 1

Kewalramani Reshma · CIK 0001735944 · Director · CEO & President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 108,711

F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 08/11/2023.

SEC source: 0000875320-23-000060 · wk-form4_1702675985.xml · nonDerivative · entry 2

LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,071

F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 08/04/2023.

SEC source: 0000875320-23-000060 · wk-form4_1702675985.xml · nonDerivative · entry 1

LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 9,171

F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 08/04/2023.

F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F3 · price: Open market sales reported on this line occurred at a weighted average price of $399.41 (range $399.00 to $399.97).

SEC source: 0000875320-23-000052 · wk-form4_1701896824.xml · nonDerivative · entry 1

Thornberry Nancy · CIK 0001797826 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,136

F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date.

SEC source: 0000875320-23-000043 · wk-form4_1700600822.xml · nonDerivative · entry 1

WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 46,693

F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1, which was entered into on 08/18/2023.

F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F3 · price: Open market sales reported on this line occurred at a weighted average price of $349.88 (range $349.76 to $350.00).

SEC source: 0000875320-23-000039 · wk-form4_1700255434.xml · nonDerivative · entry 1

ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,038

F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1, which was entered into on 5/10/2023.

SEC source: 0000875320-23-000041 · wk-form4_1700255780.xml · nonDerivative · entry 1

Sachdev Amit · CIK 0001406338 · EVP Chief Patient & Ext Af Off

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 58,814

F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 05/09/2023.

SEC source: 0000875320-23-000037 · wk-form4_1700169311.xml · nonDerivative · entry 1

Bozic Carmen · CIK 0001790029 · EVP and CMO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 29,302

F1 · kind: Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 05/30/2023.

SEC source: 0000875320-23-000035 · wk-form4_1700082955.xml · nonDerivative · entry 1

Kewalramani Reshma · CIK 0001735944 · Director · CEO & President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 113,809

F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 08/11/2023.

SEC source: 0000875320-23-000033 · wk-form4_1699477872.xml · derivative · entry 3

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,250

Underlying: Common Stock · 11,250 shares

Expires 2025-05-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Fully vested.

SEC source: 0000875320-23-000033 · wk-form4_1699477872.xml · nonDerivative · entry 2

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 40,000

F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1, which was entered into on 11/04/2022.

F2 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F3 · price: Open market sales reported on this line occurred at a weighted average price of $385.00 (range $385.00 to $385.02).

SEC source: 0000875320-23-000033 · wk-form4_1699477872.xml · nonDerivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,250

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000875320-23-000025 · wk-form4_1698955627.xml · nonDerivative · entry 1

Bozic Carmen · CIK 0001790029 · EVP and CMO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 34,952

F1 · kind: Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 05/30/2023.

SEC source: 0001209191-23-053175 · doc4.xml · nonDerivative · entry 1

Bhatia Sangeeta N. · CIK 0001643921 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,901

F1 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1, which was entered into on 05/10/2023.

SEC source: 0001209191-23-053178 · doc4.xml · nonDerivative · entry 1

Bozic Carmen · CIK 0001790029 · EVP and CMO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 40,603

F1 · kind: Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 05/30/2023.

SEC source: 0001209191-23-053073 · doc4.xml · nonDerivative · entry 1

LEIDEN JEFFREY M · CIK 0001242825 · Director · Executive Chairman

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 22,425

F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1, which was entered into on 11/01/2022.

F2 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F3 · price: Open market sales reported on this line occurred at a weighted average price of $374.00 (range $374.00 to $374.02).

SEC source: 0001209191-23-052959 · doc4.xml · derivative · entry 1

MCKENZIE DIANA · CIK 0001754648 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,745.98

Underlying: Common Stock · 89.532 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.

SEC source: 0001209191-23-052961 · doc4.xml · derivative · entry 1

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,643.216

Underlying: Common Stock · 118.25 shares

Expires not disclosed

F1 · derivative.exercise_price: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.exercise_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

F1 · derivative.expiration_date: Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

SEC source: 0001209191-23-052622 · doc4.xml · nonDerivative · entry 1

Bhatia Sangeeta N. · CIK 0001643921 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,144

F1 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1, which was entered into on 05/10/2023.

SEC source: 0001209191-23-052535 · doc4.xml · nonDerivative · entry 1

Lagarde Michel · CIK 0001518973 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,132

F1 · shares: Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date.

SEC source: 0001209191-23-052202 · doc4.xml · nonDerivative · entry 1

Bozic Carmen · CIK 0001790029 · EVP and CMO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 46,254

F1 · kind: Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 05/30/2023.

SEC source: 0001209191-23-051408 · doc4.xml · nonDerivative · entry 2

Biller Jonathan · CIK 0001744749 · EVP and Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,569

F1 · kind: Transaction made pursuant to Mr. Biller's company approved trading plan under Rule 10b5-1, which was entered into on 02/27/2023.

SEC source: 0001209191-23-051408 · doc4.xml · nonDerivative · entry 1

Biller Jonathan · CIK 0001744749 · EVP and Chief Legal Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,179

SEC source: 0001209191-23-050259 · doc4.xml · nonDerivative · entry 1

Bozic Carmen · CIK 0001790029 · EVP and CMO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,905

F1 · kind: Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 05/30/2023.

SEC source: 0001209191-23-048624 · doc4.xml · nonDerivative · entry 1

Bozic Carmen · CIK 0001790029 · EVP and CMO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 57,556

F1 · kind: Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 05/30/2023.

SEC source: 0001209191-23-047309 · doc4.xml · nonDerivative · entry 1

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 48,637

F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 05/09/2023.

SEC source: 0000899243-23-018109 · doc4.xml · nonDerivative · entry 1

Sachdev Amit · CIK 0001406338 · EVP, Chief Patient Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 58,814

F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1, which was entered into on 05/09/2023.

SEC source: 0000899243-23-018112 · doc4.xml · nonDerivative · entry 1

Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off.

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 51,137

F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 05/09/2023.

SEC source: 0000899243-23-018113 · doc4.xml · derivative · entry 3

Kearney Terrence C · CIK 0001289098 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2025-05-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Fully vested.

SEC source: 0000899243-23-018113 · doc4.xml · nonDerivative · entry 2

Kearney Terrence C · CIK 0001289098 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,536

F1 · kind: Transaction made pursuant to Mr. Kearney's company approved trading plan under Rule 10b5-1, which was entered into on 05/09/2023.

SEC source: 0000899243-23-018113 · doc4.xml · nonDerivative · entry 1

Kearney Terrence C · CIK 0001289098 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,536

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000899243-23-018043 · doc4.xml · nonDerivative · entry 1

Bhatia Sangeeta N. · CIK 0001643921 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 4,386

F1 · kind: Transaction made pursuant to Dr. Bhatia's company approved trading plan under Rule 10b5-1, which was entered into on 05/10/2023.

SEC source: 0000899243-23-018044 · doc4.xml · nonDerivative · entry 1

ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 32,038

F1 · kind: Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1, which was entered into on 5/10/2023.

SEC source: 0001209191-23-042557 · doc4.xml · nonDerivative · entry 1

Kewalramani Reshma · CIK 0001735944 · Director · CEO & President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 118,906

F1 · kind: Transaction made pursuant to Dr. Kewalramani's company approved trading plan under Rule 10b5-1, which was entered into on 11/10/2022.

SEC source: 0001209191-23-042566 · doc4.xml · derivative · entry 6

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 11,250

Underlying: Common Stock · 11,250 shares

Expires 2025-05-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F7 · derivative.exercise_date: Fully vested.

SEC source: 0001209191-23-042566 · doc4.xml · nonDerivative · entry 4

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 40,000

F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1, which was entered into on 11/04/2022.

F2 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F5 · price: Open market sales reported on this line occurred at a weighted average price of $357.29 (range $357.00 to $357.38).

SEC source: 0001209191-23-042566 · doc4.xml · nonDerivative · entry 3

SACHS BRUCE I · CIK 0001197036 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 43,842

F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1, which was entered into on 11/04/2022.

F2 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4 · price: Open market sales reported on this line occurred at a weighted average price of $356.75 (range $356.00 to $356.99).